Aceclidine
Glaucoma · Rx
RxGlaucomaGlaucoma CholPreservative-free option Dark green cap
| Strength | 1.44% |
|---|---|
| Typical quantity | 25 x 0.25 mL vials (25-day) |
| Cash cost / month | Moderate · ~$20-100 |
| Drug class | Cholinergic (muscarinic) agonist / miotic, presbyopia formulation |
| Mechanism of action | Pupil-selective muscarinic agonist; contracts the iris sphincter for a sub-2mm pinhole effect while largely sparing the ciliary muscle, extending depth of focus for near vision without the accommodative spasm or myopic shift seen with pilocarpine. |
| Indication / reason for use | Presbyopia. Not indicated for glaucoma or angle-closure. |
| Usual adult dosing | 1 drop each eye, wait 2 minutes, then a second drop each eye, once daily. Onset within 30 minutes, lasts up to 10 hours. |
| Preservative | Preservative-free, single-use vials , a preservative-free option exists |
| Contact lenses | Remove lenses; reinsert after 15 minutes. |
| Common / important adverse effects | Instillation site irritation, dim vision, headache, conjunctival/ocular hyperemia; mostly mild, transient and self-resolving per trial data. |
| Contraindications & cautions | Hypersensitivity; not recommended with a known history of iritis. The usual relative cautions for miotics (peripheral retinal disease) apply. |
| Pregnancy / lactation | No adequate human data; animal studies did not show adverse effects at clinically relevant doses. Use only if clearly needed. |
| Pregnancy category (older labels) | No letter category on the current label. From DailyMed labels, checked Nov 2026. |
| Trade names | Vizz |
| Practice notes | FDA-approved July 2025 (CLARITY 1-3 trials), launched in the US October 2025. A third FDA-approved presbyopia drop, competing with Vuity (pilocarpine 1.25%) and Qlosi (pilocarpine 0.4%); aceclidine is a distinct molecule from pilocarpine, marketed on a more pupil-selective profile. |
Chair-side reference only. Dosing, contraindications and pregnancy guidance here are not exhaustive. Confirm against the current prescribing information and the patient’s full history before prescribing or advising.